52,682 trials (keyword fallback)
Renal Cancer
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR
Kidney Disease
Primary: Variability of Tacrolimus Blood Levels Measured by DBS Over Time — 2.635 ng/ml
Kidney Transplant
Primary: Time to First Therapeutic Tacrolimus Trough Concentration From Initiation of Tacrolimus Extended Release Measured in Days — 4.5; 6; 13.5 days
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Chronic Kidney Disease · Cardiac Disease
Primary: Glomerular Filtration Rate at Baseline — 56; 67 mL/mnt/1.73 m^2
HLRCC · Sporadic Papillary Renal Cell Cancer
Primary: Overall Response Rate — 72; 35 Percentage of participants
Diabetic Nephropathies · Coronary Artery Disease
Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
Kidney Disease
Primary: Number of Participants With Live Kidney Donor Activation Events — 87; 86; 88; 5 Participants
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32